Board has approved the scheme of merger of Asian Clinical Trials Ltd with the Company, subject to sanction of scheme by the Court, approval(s) of shareholders / creditors and other statutory authorities. The scheme would entail issue and allotment of 37,25,000 equity shares of Rs 2/- each at par in the Company, in the swap ratio of 149 equity shares of Rs 2/- each in the Company (Transferee Company) to the shareholders of Asian Clinical Trials Ltd (Transferor Company) for every 1000 equity share of Rs 2/- each held by them in the Transferor Company, subject to necessary approvals. Suven Life Sciences Ltd has informed BSE that pursuant to the order made by the Hon'ble High Court of Andhra Pradesh, Hyderabad, a meeting of the equity shareholders of the Company will be held on July 31, 2006, for the purpose of considering, and if thought fit, approving with or without modification, the proposed Scheme of Amalgamation of Asian Clinical Trials Ltd with the Company as embodied in the Scheme. (As Per BSE Bulletin Dated on 12/07/2006) Suven Life Sciences Limited has informed the Exchange that by an order dated June 19, 2006 in C.A. No. 558 of 2006, the Hon'ble High Court of Andhra Pradesh has directed that a meeting of the Equity Shareholders of the Applicant/Transferee Company shall be held on July 31, 2006 for the purpose of considering and if thought fit, approving with or without modification, the proposed Scheme of Amalgamation of Asian Clinical Trials Limited/Transferor Company with Suven Life Sciences Ltd/Applicant/Transferee Company as emboided in the Scheme. (As per NSE Bulletin dated on 14/07/2006) Suven Life Sciences Limited has informed the Exchange that shareholders in the Court convened meeting held on July 31,2006, have approved the Scheme of Amalgamation between the company with Asian Clinical Trials Limited. (As Per NSE Bulletin Dated on 01/08/2006) Suven Life Sciences Limited has informed the Exchange that the Hon'ble High Court of Andhra Pradesh has sanctioned the Scheme of Amalgamation between Asian Clinical Trials Limited and Suven Life Sciences Limited. The Board of Directors in their meeting held on October 30,2006 has taken on record the Orders of Hon'ble High Court and approved the notice convening the Extra-Ordinary General Meeting of the Company to be held on December 06,2006 for issue and allotment of equity shares pursuant to Scheme of Amalgamation between Asian Clinical Trials Limited (Transferor Company) and Suven Life Sciences Limited (Transferee Company). (As Per NSE Bulletin Dated on 31/10/2006) Suven Life Sciences Ltd has informed BSE that an Extra Ordinary General Meeting (EGM) of the members of the Company will be held on December 06, 2006 to issue & allot 37,25,000 equity shares of Rs 2/- each at par to the shareholders of Asian Clinical Trials Ltd (transferor company) as per the Scheme of Amalgamation between Asian clinical Trial Ltd and the Company sanctioned by the Hon'ble High Court of Andhra Pradesh vide order dated October 18, 2006. (As Per BSE Announcement Dated on 13/11/2006) Suven Life Sciences Ltd has informed BSE that the members at the Extra_Ordinary General Meeting (EGM) of the Company held on December 06, 2006 have approved and authorized the Board of Directors of the Company to issue and allot 37,25,000 equity shares of Rs 2/- each as per the scheme of amalgamation between Asian Clinical Trials Ltd (Transferor Company) and the Company (Transferee Company) as sanctioned by the Hon'ble High Court of Andhra Pradesh. Further the Company has informed that, the Board of Directors of the Company at its meeting held on December 06, 2006 has issued and allotted 37,25,000 equity shares of Rs 2/- each at par to the shareholders of Asian Clinical Trials Ltd (Transferor Company) in the exchange ratio pursuant to scheme of amalgamation between Asian Clinical Trials Ltd and the Company as sanctioned by the Hon'ble High Court of Andhra Prades. (As Per BSE Announcement Dated on 06/12/2006) Trading members of the Exchange are hereby informed that the under mentioned new securities of Suven Life Sciences Ltd. (Scrip Code: 530239, ISIN No: INE495B01020) are listed and permitted for trading on the Exchange with effect from Wednesday, April 04, 2007. Securities 37,25,000* Equity Shares of Rs.2/- each issued to the shareholders of erstwhile Asian Clinical Trials Ltd. pursuant to Scheme of Amalgamation of the Company. Dist. Nos. 25000001 to 28725000 * These shares are ranking pari-passu with the existing equity shares of the company. 2. Trading members may please note that 37,09,205 equity shares bearing distinctive nos.25000001 to 28709205 issued pursuant to the scheme of amalgamation are under lock-in till May 05, 2010 and are enfaced with the stamp of non - transferability; therefore these shares would not be good delivery in the market till then. 3. The brief particulars of the Scheme of Amalgamation are as mentioned below: a) The Scheme of Amalgamation of the company was approved by the Hon'ble High Court of Andhra Pradesh vide the Order dated November 09,2006. b) Appointed Date: April 01, 2006 c) Effective Date: October 18, 2006 d) Date of Allotment: December 06, 2006 e) Exchange Ratio - The Company has allotted 149 (One Hundred and forty nine) fully paid-up Equity Shares of Rs.2/- each of transferee company for every 1000 (One thousand) equity shares of Rs.2/- each held in Asian Clinical Trials Ltd. 4. The company's financial year ends on 31st March. 5. In case trading members require any clarification on the subject matter of the notice, they may please contact the undersigned on 22721233/34 Extn. No.8571. (As per BSE Notice dated on 03/04/2007) Trading members of the Exchange were informed vide Exchange's Notice No. 20070403-17 dated April 03, 2007 regarding listing of 37,25,000 equity shares of Rs 2/- each pursuant to the Scheme of amalgamation of Asian Clinical Trials Ltd with the company. As the Company has now sub- divided its equity share from Rs. 2 per share to Re 1/- paid up per share (Refer Notice No 20070402-6 dated April 2, 2007), the particulars of the new shares issued pursuant to amalgamation are as under: 1. The face value of the shares after split: is Re.1 each. 2. 74,50,000 new equity shares have been issued pursuant to amalgamation. 3. The distinctive Nos. of the these shares are: 50000001 to 57450000 4. 74,18,410 equity shares bearing distinctive nos. 50000001 to 57418410 issued pursuant to the scheme of amalgamation are under lock-in till May 05, 2010 and are enfaced with the stamp of non-transferability; therefore these shares would not be good delivery in the market till then All the remaining particulars stated in Notice No 20070403-17 dated April 3, 2007 remain unchanged (As per BSE Notice dated on 05/04/2007)